AU2011376333A1 - Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy - Google Patents

Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy Download PDF

Info

Publication number
AU2011376333A1
AU2011376333A1 AU2011376333A AU2011376333A AU2011376333A1 AU 2011376333 A1 AU2011376333 A1 AU 2011376333A1 AU 2011376333 A AU2011376333 A AU 2011376333A AU 2011376333 A AU2011376333 A AU 2011376333A AU 2011376333 A1 AU2011376333 A1 AU 2011376333A1
Authority
AU
Australia
Prior art keywords
dihydro
methanesulfonamide
dioxo
quinazolin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011376333A
Other languages
English (en)
Inventor
George IMBERT
Donald Johns
Klaus KUCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011376333A1 publication Critical patent/AU2011376333A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011376333A 2011-09-07 2011-09-07 Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy Abandoned AU2011376333A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
AU2011376333A1 true AU2011376333A1 (en) 2014-03-13

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011376333A Abandoned AU2011376333A1 (en) 2011-09-07 2011-09-07 Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Country Status (10)

Country Link
EP (1) EP2753331A1 (enExample)
JP (1) JP2014525474A (enExample)
KR (1) KR20140071405A (enExample)
CN (1) CN103889427A (enExample)
AU (1) AU2011376333A1 (enExample)
BR (1) BR112014005210A2 (enExample)
CA (1) CA2846503A1 (enExample)
IN (1) IN2014DN01791A (enExample)
MX (1) MX2014002693A (enExample)
WO (1) WO2013036224A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
EP1677790A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
EP1677789A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
EP1677788A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes iii
CN1933838A (zh) 2004-02-12 2007-03-21 默克公司 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
US20090005363A1 (en) 2005-12-20 2009-01-01 Ralf Glatthar Organic Compounds
BR112012010201A2 (pt) * 2009-11-03 2017-08-08 Lupin Ltd formulação de libertação modificada da lacosamida

Also Published As

Publication number Publication date
CN103889427A (zh) 2014-06-25
JP2014525474A (ja) 2014-09-29
BR112014005210A2 (pt) 2017-03-21
WO2013036224A1 (en) 2013-03-14
EP2753331A1 (en) 2014-07-16
IN2014DN01791A (enExample) 2015-05-15
MX2014002693A (es) 2014-06-04
KR20140071405A (ko) 2014-06-11
CA2846503A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
US10111889B2 (en) Uses of ganaxolone
Rogawski et al. Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
CA2691812A1 (en) A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-b) indoles, its pharmacological compound and application method
JP2014530881A (ja) 軸索再生および神経機能を促進するための方法および組成物
CA2674460C (en) 3-substituted-h.2.31-benzotriazinone compound for enhancing glutamatergic synaptic responses
US7226949B2 (en) Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
EP3188727B1 (en) Tasimelteon for treating smith-magenis syndrome
EP3258930A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
AU2011376333A1 (en) Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
CA2814828A1 (en) Method of treatment for mental disorders
WO2006121919A2 (en) Methods of treating obsessive compulsive disorder
AU2010274921A1 (en) 1H-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis
CA2526458A1 (en) Further therapeutic use of zolpidem
AU2011268865A1 (en) Use of 1H-quinazoline-2,4-diones
ZA200509646B (en) Further therapeutic use of zolpidem

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application